Pharma Faces Phase III Licensing Drought; Separate R&D “Pools” May Help
Executive Summary
Pharmaceutical companies should separate R&D budgets for internal and external deals, Bayer Licensing & Acquisitions Associate Director Ann Kraft suggested
You may also be interested in...
GSK Decreases Reliance On Late-Stage Licenses, Citing Strength In R&D
GlaxoSmithKline is reducing its reliance on late-stage in-licensing deals following an R&D restructuring program that has yielded a burgeoning pipeline, CEO J.P. Garnier told analysts
GSK Decreases Reliance On Late-Stage Licenses, Citing Strength In R&D
GlaxoSmithKline is reducing its reliance on late-stage in-licensing deals following an R&D restructuring program that has yielded a burgeoning pipeline, CEO J.P. Garnier told analysts
Lilly Sees Value In Biotech R&D, Will Focus On Partnerships Over Acquisitions
Lilly is placing more emphasis on implementing its strategic partnerships than completing acquisitions, CEO Sidney Taurel said at a conference sponsored by The Economist in Philadelphia Nov. 19